Literature DB >> 15105794

Safety concerns and health benefits associated with oral contraception.

Ronald Burkman1, James J Schlesselman, Miriam Zieman.   

Abstract

Since the introduction of hormonal contraceptives in the 1960s, there have been a variety of both health benefits and safety concerns attributed to their use. In most instances, the noncontraceptive benefits of oral contraceptives (OCs) outweigh the potential cardiovascular risks. In fact, the probability of a patient experiencing a cardiovascular event while taking a low-dose OC is very low. However, smoking, hypertension, obesity, and diabetes are risk factors that must be taken into account when prescribing OCs. The neoplastic effects of hormonal contraceptives have been extensively studied, and recent meta-analyses indicate that there is a reduction in the risk of endometrial and ovarian cancer, a possible small increase in the risk for breast and cervical cancer, and an increased risk of liver cancer. Finally, many women will experience noncontraceptive health benefits with OCs that expand far beyond pregnancy prevention. Some of these benefits include reduction in menstrual-related symptoms, fewer ectopic pregnancies, a possible increase in bone density, and possible protection against pelvic inflammatory disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105794     DOI: 10.1016/j.ajog.2004.01.061

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  26 in total

1.  Reciprocal expression of survivin and SMAC/DIABLO in primary breast cancer.

Authors:  A Mansour; M Nabil; R Ali-Labib; H Said; F Annos
Journal:  Med Oncol       Date:  2011-12-08       Impact factor: 3.064

Review 2.  Male hormonal contraception: potential risks and benefits.

Authors:  Niloufar Ilani; Ronald S Swerdloff; Christina Wang
Journal:  Rev Endocr Metab Disord       Date:  2011-06       Impact factor: 6.514

3.  Oral contraceptive use and depression among adolescents.

Authors:  Sarah McKetta; Katherine M Keyes
Journal:  Ann Epidemiol       Date:  2018-10-13       Impact factor: 3.797

4.  Oral contraceptive use as a determinant of plasma concentrations of perfluoroalkyl substances among women in the Norwegian Mother and Child Cohort (MoBa) study.

Authors:  Elise L Rush; Alison B Singer; Matthew P Longnecker; Line S Haug; Azemira Sabaredzovic; Elaine Symanski; Kristina W Whitworth
Journal:  Environ Int       Date:  2017-12-20       Impact factor: 9.621

5.  Medical students' attention to multiple risk behaviors: a standardized patient examination.

Authors:  Judith J Prochaska; Kathleen Gali; Bernie Miller; Karen E Hauer
Journal:  J Gen Intern Med       Date:  2012-01-04       Impact factor: 5.128

6.  Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.

Authors:  Ida Martinelli; Anthonie W A Lensing; Saskia Middeldorp; Marcel Levi; Jan Beyer-Westendorf; Bonno van Bellen; Henri Bounameaux; Timothy A Brighton; Alexander T Cohen; Mila Trajanovic; Martin Gebel; Phuong Lam; Philip S Wells; Martin H Prins
Journal:  Blood       Date:  2015-12-22       Impact factor: 22.113

7.  A case-control study of oral contraceptive use and incident breast cancer.

Authors:  Lynn Rosenberg; Yuqing Zhang; Patricia F Coogan; Brian L Strom; Julie R Palmer
Journal:  Am J Epidemiol       Date:  2008-12-13       Impact factor: 4.897

8.  Ethinyl oestradiol administration in women suppresses synthesis of collagen in tendon in response to exercise.

Authors:  Mette Hansen; Satu O Koskinen; Susanne G Petersen; Simon Doessing; Jan Frystyk; Allan Flyvbjerg; Eva Westh; S Peter Magnusson; Michael Kjaer; Henning Langberg
Journal:  J Physiol       Date:  2008-04-17       Impact factor: 5.182

Review 9.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

Review 10.  Exposures to synthetic estrogens at different times during the life, and their effect on breast cancer risk.

Authors:  Leena Hilakivi-Clarke; Sonia de Assis; Anni Warri
Journal:  J Mammary Gland Biol Neoplasia       Date:  2013-02-08       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.